All In Biotech

Drug Trial Radar · NCT07951086

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid Arthritis

A Phase 2, Randomized, Double-blind, Placebo Controlled Multicenter Study of DDY391 Assessing Efficacy, Safety and Tolerability in Participants With Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jan 26, 2027

Primary completion

May 18, 2028

Study completion Jun 15, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2 study is: 1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with moderate to severe active rheumatoid arthritis (RA). 2. to provide information about dose selection and study design for subsequent clinical development.

Conditions

  • Rheumatoid Arthritis

Interventions

  • DDY391Drug

    DDY391

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants achieving American College of Rheumatology 50 (ACR50) responseTime frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.